The development of neutralizing antibodies (NAbs) against interferon-b (IFNb) reduces clinical efficacy and markers of bioactivity in patients with multiple sclerosis (MS), although it has also been shown that a poor response to IFNb coincided with unexpectedly low NAb levels. To try and resolve this incoherency, this study investigated 2822 patients referred to a NAb testing facility. The reason for NAb testing was indicated for 2506 patients: routine testing (76%), worsening of disease (14%) and other reasons (10%). Overall, 31% of patients were NAb positive and 17% had titres high enough to obliterate IFNb bioactivity. The frequency of NAbs was similar in patients in the routine testing group compared with the worsening group. Samples showing high titres failed to be associated with worsening of symptoms. The study failed to show low NAb levels in patients responding poorly to IFNb. It is concluded that it is not possible to predict NAb status by clinical impression of treatment response. This is likely to be an effect of the partial efficacy of IFNb. Thus routine testing for NAbs must be carried out in order to identify NAb status in patients with MS.
Introduction
Two to 47% of patients with multiple sclerosis (MS) treated with interferon-β (IFNβ) develop neutralizing antibodies (NAbs) as a consequence of the treatment. 1 The development of NAbs appears to depend on IFNβ preparation, frequency and route of administration. 1 There is little doubt that high titre NAbs abolish the bioavailability of IFNβ, 2 and there is also growing and consistent evidence that persistent NAbs reduce the clinical and magnetic resonance imaging (MRI) efficacy of IFNβ preparations. 3 -7 Accordingly, a panel of experts from European Federation of Neurological Societies (EFNS) recently recommended that testing for NAbs should be avaliable to all IFNβ-treated patients and that routine sampling should be performed after 12 and 24 months. 8 This view is based on the presumption that it is clinically difficult to U Rot, A Sominanda, A Fogdell-Hahn et al. Neutralizing antibodies and clinical worsening determine whether a patient has had a biological effect of treatment from the clinical course. MS relapses may occur after long intervals and IFNβ in itself only has a partial effect on the rate of MS relapses, with an approximately 30% reduction reported. 9 In the relapsing/remitting phase of MS, the progression of the disease is also modestly reduced by IFNβ treatment but, in the absence of relapses, the effect of IFNβ in secondary progression is negligible.
The results of a recent survey by Goodin et al. 10 of samples obtained from patients reported to be doing poorly on IFNβ-1b were unexpected. The frequency of NAbs in a large sample of MS patients from the USA was approximately 20% which, in comparison with 38% in a population-based sample from Australia, led the authors to question the importance of NAbs. 10, 11 Consequently, the present study has investigated the reasons for testing the serum samples of a large group of MS patients receiving IFNβ treatment and referred to a routine NAb testing facility. 
Patients and methods

PATIENTS
SAMPLE COLLECTION AND ASSAY
Peripheral venous blood was collected at least 48 h after the last IFNβ injection and the serum was separated and frozen before shipping to the laboratory. The presence of NAbs to IFNβ was determined using the myxovirus protein A (MxA) induction assay as previously described. 12 The NAb titre was defined according to the Kawade formula as the serum dilution that inhibits the activity of 10 IU/ml of IFNβ to an apparent activity of 1 IU/ml. 13 Patients were considered as NAb positive with titres ≥ 10 TRU/ml (ten times reduction units/ml). Based on our in vivo MxA mRNA bioavailability data from NAbpositive patients, positive samples were further categorized as low-positive (10 -49 TRU/ml), medium (50 -149 TRU/ml), high (150 -600 TRU/ml) and very high (> 600 TRU/ml). 14 
STATISTICAL ANALYSIS
All statistical analyses were performed using the GraphPad Prism ® program, version 3.03 (GraphPad Software, San Diego, CA, USA). The Mann-Whitney U-test and Fisher's exact test were used as appropriate. A P-value < 0.05 was considered to be statistically significant. Patients treated with Betaferon ® had a significantly longer duration of treatment than patients treated with Avonex ® (P < 0.0001) and Rebif ® (P < 0.0001).
Results
TABLE 1: Demographic characteristics of 2822 multiple sclerosis patients treated with different interferon-b (IFNb) formulations
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Pharma, Berlin, Germany). The demographic characteristics of patients treated with the three different IFNβ preparations are presented in Table 1 .
A total of 884 (31%) patients were NAb positive: 83 (11%) of the Avonex ® -treated patients, 499 (36%) of the Rebif ® -treated patients, and 302 (43%) of the Betaferon ®treated patients. Avonex ® -treated patients were significantly less often seropositive than patients treated with Rebif ® (P < 0.0001) and Betaferon ® (P < 0.0001). Patients treated with Rebif ® were significantly less often seropositive than patients treated with Betaferon ® (P = 0.0032).
Altogether 490 (17%) patients showed high or very high titre NAbs: 40 (5%) of the Avonex ® -treated patients, 137 (20%) of the Betaferon ® -treated patients, and 313 (23%) of the Rebif ® -treated patients.
The Characteristics of the 2506 patients divided according to the three different indications for testing are shown in Table 2 . There were 1810 (72%) women overall and no gender difference between the three groups. Patients with a worsening indication for testing were significantly younger than patients with other indications for testing (P = 0.0227). Patients with other indications for testing had a significantly longer duration of treatment than patients with worsening indicated (P = 0.001) and patients with a routine indication (P = 0.0001).
Betaferon ® -treated patients were significantly more often tested for an apparent clinical worsening compared to patients treated with Avonex ® (P = 0.05) or U Rot, A Sominanda, A Fogdell-Hahn et al.
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Rebif ® (P = 0.0265). Patients treated with Avonex ® were significantly more often tested routinely than patients treated with Betaferon ® (P = 0.0008) or Rebif ® (P = 0.0288).
Among 363 patients tested due to a clinical impression of worsening of disease, 112 (31%) were NAb positive. In comparison, 562 (30%) of 1904 patients tested routinely were NAb positive. Similarly, 64 patients (18%) tested due to a clinical impression of worsening showed high or very high titre (> 150 TRU/ml) compared with 309 (16%) of patients tested routinely. These results are not statistically significant (Fig.  1) . In all titre categories, the occurrence of NAb-positive samples was similar regardless of whether the patient had been referred for routine testing or due to a worsening of clinical symptoms.
Following stratification of the data according to treatment duration (prompted by previous findings, most clearly shown in the PRISMS study, 4 of a delay of several months before an increased relapse rate is observed following conversion to NAb positivity), the present study found no significant difference among patients treated for ≥ 36 months (34% NAb positive in worsening patients and 31% among those tested routinely) or < 36 months (30% positive in worsening patients and 29% in those tested routinely).
Discussion
The present large cross-sectional study from an independent routine laboratory has reported on the indications for testing for NAbs in IFNβ-treated MS patients. The results clearly show that a clinical impression of worsening failed to be predictive for the presence of NAbs.
Routine 
Characteristics of multiple sclerosis patients (n = 2506) treated with different interferon-b (IFNb) formulations in relation to the reasons for referral to a neutralizing antibody (NAB) testing facility
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are best illustrated by a Danish study in which patients persistently positive for NAbs for IFNβ had more relapses and a significantly shortened interval to a second relapse compared to NAb-negative patients. 7 Among randomized clinical trials, data from the PRISMS-4 study likewise showed that patients who developed NAbs to subcutaneous IFNβ-1a (Rebif ® ) had a higher frequency of relapses and active T2 lesions on MRI than NAb-negative patients. 4 Data from the European IFNβ-1a dose comparison study showed that NAbs against intramuscular IFNβ-1a (Avonex ® ) reduced the therapeutic benefit of the drug as measured by relapses, MRI activity and even change in disability as assessed by the Expand Disability Status Score (EDSS). 5 Furthermore, in a study from Denmark, a reduction in biological activity of IFNβ measured by blood levels of neopterin and β 2 -microglobulin strongly correlated with a loss of treatment effect on MRI in NAb-positive patients. 15 We have also recently reported that NAb titres > 150 TRU/ml reduced the bioactivity of IFNβ by > 80%, and titres > 600 TRU/ml were invariably associated with abolished bioactivity. 14 Despite several lines of evidence consistently pointing towards a loss of efficacy of IFNβ in the presence of NAbs, laboratories that routinely determine NAbs are scarce and few cross-sectional studies have been reported.
In this perspective, the results presented by Goodin and colleagues 10, 11 are surprising. For one of the three populations in the study, the Australian group of patients in which NAb testing was mandatory, the NAb frequency results were similar to those previously reported in similar cohorts, including a cross-sectional study. 1, 3, 8 In contrast, samples from the European and American groups were sent in voluntarily from practising neurologists as a response to an offer from the manufacturer of IFNβ-1b to test for NAbs in cases of a clinical impression In these groups, the NAb frequency was surprisingly much lower than the expected frequency of about 40% 1 , ranging from 21% to 27%. 10 These intriguing results triggered the current analysis of the data set reported in this investigation. A partially similar result was obtained in the present study: patients with a worsening of MS did not show a higher frequency of NAbs than those tested routinely. For patients with NAb titres high enough to obliterate bioactivity, i.e. patients with high or very high titres, there was a very small, albeit not statistically significant difference in the levels of NAbs in patients tested due to worsening of disease (18%) in comparison with those tested routinely (16%). No trace of a paradoxical opposite relationship reported by Goodin et al. 10 was seen in the present study.
In terms of the importance of NAbs, the obvious failure of the present study to predict NAb status requires explanation. The most obvious reason is likely to be the varied situations in which a patient may seem to fail on IFNβ. Treatment with IFNβ is partially efficacious, reducing the relapse rate by only 30%. 9 Thus, 70% of all relapses at the group level would occur anyway, each time potentially indicating a loss of efficacy. In addition, patients may progress in the absence of a relapse, such as in early secondary progression, the kind of progression that IFNβ is unlikely to prevent. 16 Finally, it is likely that a number of patients on treatment will, in fact, already be in their secondary progressive phase and receiving IFNβ, since no diseasemodifying treatment is available for this patient group. For example, 134 of the 632 (21%) MS patients from a single tertiary centre who started with immunomodulatory treatment between October 1995 and February 2004 had secondary progressive MS 17 and, similarly, unpublished data from the Swedish MS Registry show that approximately 25% of IFNβ-treated MS patients have secondary progressive MS.
Some differences in the frequency of worsening of symptoms between different IFNβ preparations were recorded in the present study, however these are most likely explained by bias, most importantly in terms of patient selection for the different preparations of IFNβ. Patients treated with Betaferon ® were more often selected for NAb testing because of a worsening of disease compared to patients treated with Avonex ® and Rebif ® . This may be because Betaferon ®treated patients were older and had a longer duration of treatment than patients treated with the other two preparations. On the other hand, patients treated with Avonex ® were more often referred for routine testing. There is some controversy in this observation because less frequent routine testing would be expected in Avonex ® -treated patients, since it is known that this drug only rarely induces NAbs. 8 Conversely, the Avonex ®treated patients were younger than patients on Betaferon ® . The Avonex ® -treated patients also had a shorter duration of the treatment than either the Betaferon ® and Rebif ®treated patients and, thus, were more likely to be stable and sampled routinely. In addition, since there is some evidence of better efficacy with high dosage and high frequency IFNβ treatment, it might be expected that the lower dose, lower frequency regime of Avonex ® may be more often prescibed to patients with less active MS. 18, 19 In a non-randomized cohort of patients, biases can, however, make comparisons between preparations scientifically questionable.
One limitation of the present study is that data collection from clinic referral forms is
